NEW YORK, Feb. 8, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announces that Susanne Wilke PhD, Neurotrope's Chief Executive Officer, and Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer, are scheduled to present at the 2017 BIO CEO & Investor Conference being held on February 13th-14th, 2017 at the Waldorf Astoria Hotel in New York City.
The Company's presentation will take place on Monday, February 13th, 2017 at 10:30am EST in the Conrad Room during the conference's CNS/Neurological Track. In addition, any investors attending the conference that wish to meet with Neurotrope's management can also contact our Director of Communications, Jeffrey Benison.
Neurotrope will announce topline efficacy results for its Phase 2, randomized, double blind, placebo controlled trial in 148 patients with moderate to severe AD patients this coming April. The Company's lead drug, bryostatin-1, has demonstrated, in animal models, efficacy for restorative synaptogenesis, prevention of neuronal death, and anti-amyloid, anti-tau metabolism via the activation of PKC epsilon. The restorative therapeutic potential of bryostatin-1 and bryostatin-like activators, may be fundamental to a number of neuro-degenerative pathways and neurologic indications including AD, Fragile X syndrome (FXS), stroke, traumatic brain injury (TBI), and depression.
A live and 90 day archived webcast of the presentation will be available at
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded biotech companies. The conference's mission is to support industry-wide success, and to present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.
Neurotrope is conducting a Phase 2 clinical trial of bryostatin in the treatment of moderate to severe Alzheimer's disease, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people, establishing a large safety database.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin for Alzheimer's disease and other cognitive diseases, and the Company's ability to list its common shares on a major stock exchange. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, the Company's inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2015 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. The Company does not undertake to update these forward-looking statements.
Please visit www.neurotropebioscience.com for further information.
For additional information, please contact:
Neurotrope Bioscience, Inc.
Jeffrey Benison, Director of Corporate Communications
212.334.8709 or 516.286.6099
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotrope-bioscience-to-present-at-the-19th-annual-bio-ceo--investor-conference-2017-300404063.html
SOURCE Neurotrope, Inc.